8/9/2021 7:33:35 AM
Liminal BioSciences To Sell Its Rare Pediatric Disease Priority Review Voucher For $105 Mln
6/23/2021 8:31:53 AM
Liminal BioSciences Inks Share Purchase Agreement For Sale Of Remaining Plasma-derived Business With Kedrion
6/4/2021 3:44:45 PM
Liminal BioSciences Announces FDA Approval For Its Biologics License Application For Ryplazim
5/17/2021 8:42:36 AM
Liminal BioSciences Enters Agreement With Kedrion To Divest Plasma Collection And Plasma-Derived Therapeutics Business
1/12/2021 9:13:14 AM
Liminal BioSciences Gets FDA Approval For US-based Plasma Collection Center
12/15/2020 9:22:47 AM
Liminal BioSciences Says First Subject Dosed In Phase 1 Multiple Ascending Dose Clinical Trial Of Fezagepras
11/8/2020 7:32:36 PM
Liminal BioSciences FDA Extends Review Period For Ryplazim BLA To June 5, 2021 From March 5, 2021
10/30/2020 8:34:27 AM
Liminal BioSciences Announces Private Placement Financing Of $30 Mln
9/21/2020 8:22:06 AM
Liminal BioScience : FDA Assigns PDUFA Target Action Date Of March 5
9/8/2020 6:05:26 AM
Liminal BioSciences Announces Resubmission Of BLA For Ryplazim For Treatment Of Congenital Plasminogen Deficiency